ZTS

Zoetis's stock price has experienced a significant decline over the past six months, influenced by the company's Q1 2026 earnings report, which missed expectations. The company lowered its full-year 2026 guidance, citing a more challenging operating environment, particularly softer demand for companion animal products in the U.S. The company has faced pressure from generic competition, as seen with its respiratory drug Draxxin. A notable event impacting the stock was the controversy surrounding Librela, an osteoarthritis treatment for dogs, which faced backlash due to reported side effects. In a positive development, Zoetis agreed to acquire Neogen's animal genomics business for $160 million in March 2026.